{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Head+and+Neck&page=5", "query": { "condition": "Cancer, Head and Neck", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 3293, "total_pages": 330, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Head+and+Neck&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Head+and+Neck&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T05:13:13.384Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03818542", "title": "A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "ABBV-181", "type": "DRUG" }, { "name": "ABBV-368", "type": "DRUG" }, { "name": "ABBV-927", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2020-01-22", "completion_date": "2020-09-23", "has_results": false, "last_update_posted_date": "2020-12-31", "last_synced_at": "2026-10-09T05:13:13.384Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03818542" }, { "nct_id": "NCT04276454", "title": "Lymphedema Treatment in Head and Neck Cancer Patients", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Flexitouch Plus system", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Endeavor Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 0, "start_date": "2020-04-23", "completion_date": "2020-04-23", "has_results": false, "last_update_posted_date": "2020-08-13", "last_synced_at": "2026-10-09T05:13:13.384Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04276454" }, { "nct_id": "NCT03630120", "title": "Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid Cancer", "Thyroid Cancer, Medullary", "Differentiated Thyroid Cancer", "Papillary Thyroid Cancer", "Follicular Thyroid Cancer", "Poorly Differentiated Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Vandetanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2018-08-06", "completion_date": "2019-12-05", "has_results": true, "last_update_posted_date": "2021-07-14", "last_synced_at": "2026-10-09T05:13:13.384Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03630120" }, { "nct_id": "NCT00451880", "title": "Study of XL281 in Adults With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Non-small-cell Lung Cancer", "Colorectal Cancer", "Papillary Thyroid Cancer", "Melanoma" ], "interventions": [ { "name": "XL281", "type": "DRUG" }, { "name": "famotidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2007-02", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2011-10-13", "last_synced_at": "2026-10-09T05:13:13.384Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Tampa, Florida • Detroit, Michigan + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00451880" }, { "nct_id": "NCT01385748", "title": "Efficacy and Safety Study of Clonidine Lauriad® to Treat Oral Mucositis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oral Mucositis" ], "interventions": [ { "name": "Clonidine Lauriad® 50µg", "type": "DRUG" }, { "name": "Clonidine Lauriad® 100µg", "type": "DRUG" }, { "name": "Placebo Lauriad®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Valerio Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 183, "start_date": "2010-04", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2017-11-28", "last_synced_at": "2026-10-09T05:13:13.384Z", "location_count": 19, "location_summary": "Sun City, Arizona • Corona, California • Duarte, California + 16 more", "locations": [ { "city": "Sun City", "state": "Arizona" }, { "city": "Corona", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01385748" }, { "nct_id": "NCT00130689", "title": "Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer", "Neoplasm Metastasis" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2005-07", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2015-05-14", "last_synced_at": "2026-10-09T05:13:13.384Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Peabody, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Peabody", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00130689" }, { "nct_id": "NCT00798746", "title": "Quality of Life After Esophagectomy for Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "Telephone Questionnaire", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2008-11", "completion_date": "2010-05", "has_results": false, "last_update_posted_date": "2012-07-31", "last_synced_at": "2026-10-09T05:13:13.384Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00798746" }, { "nct_id": "NCT04505553", "title": "Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Appendix Carcinoma", "Colon Carcinoma", "Esophageal Carcinoma", "Gastric Carcinoma", "Liver and Intrahepatic Bile Duct Carcinoma", "Malignant Digestive System Neoplasm", "Pancreatic Carcinoma", "Rectal Carcinoma", "Small Intestinal Carcinoma", "Anal Carcinoma", "Digestive System Carcinoma", "Digestive System Neuroendocrine Tumor", "Pancreatic Neuroendocrine Tumor" ], "interventions": [ { "name": "Acupuncture Therapy", "type": "PROCEDURE" }, { "name": "Acupressure Therapy", "type": "PROCEDURE" }, { "name": "Oral Cryotherapy", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2021-06-01", "completion_date": "2024-03-31", "has_results": true, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-10-09T05:13:13.384Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04505553" }, { "nct_id": "NCT00848042", "title": "Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "AuroLase Therapy", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Nanospectra Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 11, "start_date": "2008-04", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2017-02-09", "last_synced_at": "2026-10-09T05:13:13.384Z", "location_count": 2, "location_summary": "Goodyear, Arizona • Houston, Texas", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00848042" }, { "nct_id": "NCT03144661", "title": "An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma (HCC)", "Cholangiocarcinoma", "Esophageal Cancer", "Nasopharyngeal Cancer", "Ovarian Cancer", "Solid Tumors" ], "interventions": [ { "name": "INCB062079", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2017-05-25", "completion_date": "2020-06-10", "has_results": false, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-10-09T05:13:13.384Z", "location_count": 3, "location_summary": "Birmingham, Alabama • New York, New York • Toledo, Ohio", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "New York", "state": "New York" }, { "city": "Toledo", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03144661" } ] }